These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 29863899)

  • 21. Assessment of asthma control: the SERENA study.
    Corrado A; Renda T; Polese G; Rossi A;
    Respir Med; 2013 Nov; 107(11):1659-66. PubMed ID: 24045118
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial.
    Wenzel S; Castro M; Corren J; Maspero J; Wang L; Zhang B; Pirozzi G; Sutherland ER; Evans RR; Joish VN; Eckert L; Graham NM; Stahl N; Yancopoulos GD; Louis-Tisserand M; Teper A
    Lancet; 2016 Jul; 388(10039):31-44. PubMed ID: 27130691
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association between previous health care use and initiation of inhaled corticosteroid and long-acting beta2-adrenergic agonist combination therapy among US patients with asthma.
    Blanchette CM; Culler SD; Ershoff D; Gutierrez B
    Clin Ther; 2009 Nov; 31(11):2574-83. PubMed ID: 20110003
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Daily vs. intermittent inhaled corticosteroids for recurrent wheezing and mild persistent asthma: a systematic review with meta-analysis.
    Rodrigo GJ; Castro-Rodríguez JA
    Respir Med; 2013 Aug; 107(8):1133-40. PubMed ID: 23769720
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-acting beta2 agonists for the treatment of chronic asthma in children under the age of 12 years.
    Main C; Shepherd J; Anderson R; Rogers G; Thompson-Coon J; Liu Z; Hartwell D; Loveman E; Green C; Pitt M; Stein K; Harris P; Frampton GK; Smith M; Takeda A; Price A; Welch K; Somerville M
    Health Technol Assess; 2008 May; 12(20):1-174, iii-iv. PubMed ID: 18485272
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of long-acting beta-agonists and inhaled steroids in asthma: meta-analysis of observational studies.
    Hirst C; Calingaert B; Stanford R; Castellsague J
    J Asthma; 2010 May; 47(4):439-46. PubMed ID: 20528600
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs. high-dose salmeterol/fluticasone.
    Bousquet J; Boulet LP; Peters MJ; Magnussen H; Quiralte J; Martinez-Aguilar NE; Carlsheimer A
    Respir Med; 2007 Dec; 101(12):2437-46. PubMed ID: 17905575
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Zafirlukast improves asthma control in patients receiving high-dose inhaled corticosteroids.
    Virchow JC; Prasse A; Naya I; Summerton L; Harris A
    Am J Respir Crit Care Med; 2000 Aug; 162(2 Pt 1):578-85. PubMed ID: 10934090
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-acting beta2-agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma.
    Ducharme FM; Lasserson TJ; Cates CJ
    Cochrane Database Syst Rev; 2006 Oct; (4):CD003137. PubMed ID: 17054161
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Stepping down from combination asthma therapy: The predictors of outcome.
    Koskela HO; Purokivi MK; Kokkarinen J
    Respir Med; 2016 Aug; 117():109-15. PubMed ID: 27492520
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effectiveness of drug treatment strategies to prevent asthma exacerbations and increase symptom-free days in asthmatic children: a network meta-analysis.
    Zhao Y; Han S; Shang J; Zhao X; Pu R; Shi L
    J Asthma; 2015 Oct; 52(8):846-57. PubMed ID: 26061910
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of the effects of zafirlukast 40 mg b.i.d. in addition to preexisting therapy of high-dose inhaled steroids on symptomatic patients with reversible respiratory obstruction: preliminary data.
    Centanni S; Santus P; Casanova F; Di Marco F; Brazzola G; Canonica GW
    Drugs Exp Clin Res; 2000; 26(4):133-8. PubMed ID: 11109513
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-acting beta-agonist treatment in patients with persistent asthma already receiving inhaled corticosteroids.
    Hancox RJ; Taylor DR
    BioDrugs; 2001; 15(1):11-24. PubMed ID: 11437672
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Asthma exacerbation rates in adults are unchanged over a 5-year period despite high-intensity therapy.
    Schatz M; Meckley LM; Kim M; Stockwell BT; Castro M
    J Allergy Clin Immunol Pract; 2014; 2(5):570-4.e1. PubMed ID: 25213050
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combination ICS/fast-onset LABA inhaler as maintenance and reliever therapy: the future for uncontrolled adult asthma?
    Patel M; Pilcher J; Beasley R
    Expert Rev Respir Med; 2013 Oct; 7(5):451-4. PubMed ID: 24138688
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacologic interventions to reduce the risk of asthma exacerbations.
    O'Byrne PM
    Proc Am Thorac Soc; 2004; 1(2):105-8. PubMed ID: 16113421
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhaled corticosteroids or long-acting beta-agonists alone or in fixed-dose combinations in asthma treatment: a systematic review of fluticasone/budesonide and formoterol/salmeterol.
    Frois C; Wu EQ; Ray S; Colice GL
    Clin Ther; 2009 Dec; 31(12):2779-803. PubMed ID: 20110019
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Application of multicategory exposure marginal structural models to investigate the association between long-acting beta-agonists and prescribing of oral corticosteroids for asthma exacerbations in the Clinical Practice Research Datalink.
    Ali AK; Hartzema AG; Winterstein AG; Segal R; Lu X; Hendeles L
    Value Health; 2015 Mar; 18(2):260-70. PubMed ID: 25773561
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tiotropium improves lung function, exacerbation rate, and asthma control, independent of baseline characteristics including age, degree of airway obstruction, and allergic status.
    Kerstjens HA; Moroni-Zentgraf P; Tashkin DP; Dahl R; Paggiaro P; Vandewalker M; Schmidt H; Engel M; Bateman ED
    Respir Med; 2016 Aug; 117():198-206. PubMed ID: 27492532
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial.
    FitzGerald JM; Bleecker ER; Nair P; Korn S; Ohta K; Lommatzsch M; Ferguson GT; Busse WW; Barker P; Sproule S; Gilmartin G; Werkström V; Aurivillius M; Goldman M;
    Lancet; 2016 Oct; 388(10056):2128-2141. PubMed ID: 27609406
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.